To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …

Over 65% of people with obesity display the metabolic-associated fatty liver disease
(MAFLD), which can manifest as steatohepatitis, fibrosis, cirrhosis, or liver cancer. The …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in
Western societies and a major cause of hepatic disease worldwide. Its more severe type …

The prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes
mellitus (T2DM) is increasing and there is an urgent need for new treatment strategy to …

Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver
disease worldwide. Due to its association with obesity and diabetes and the fall in hepatitis …

Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD),
often regarded as the hepatic manifestation of the metabolic syndrome, increases worldwide …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is
associated with various metabolic diseases, including type 2 diabetes mellitus. There are no …

There are no licensed drugs for nonalcoholic fatty liver disease (NAFLD), and there is a lack
of consensus on the best outcome measures for controlled trials. This systematic review …

Non-alcoholic fatty liver disease (NAFLD) is the predominant cause of chronic liver disease
worldwide. NAFLD progresses in some cases to non-alcoholic steatohepatitis (NASH) …